Ousia Pharma develops peptide-drug conjugates that target synaptic plasticity modulators to treat cognitive disorders and metabolic diseases. The company aims to improve the health and quality of life for individuals affected by obesity and related metabolic conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for cognitive and metabolic disorders often lack specificity, leading to systemic side effects and limited efficacy in targeting the underlying causes of disease. Delivering therapeutics to the brain remains a significant challenge due to the blood-brain barrier.
Solution
Ousia Pharma is developing peptide-drug conjugates (PDCs) that selectively deliver synaptic plasticity modulators to the brain for treating cognitive and metabolic disorders. Their targeted approach utilizes peptides to transport therapeutic payloads across the blood-brain barrier, directly modulating synaptic function. By focusing on the essence of disease mechanisms, Ousia Pharma aims to create effective and safe pharmacotherapies that improve the health and lives of individuals affected by these disorders. The company's pipeline focuses on novel therapeutic strategies using peptide-drug conjugates.
Target Audience
The primary target audience includes individuals affected by cognitive disorders and metabolic diseases, as well as healthcare providers seeking more effective and targeted treatment options.
Features
- Peptide-drug conjugates for targeted delivery of therapeutics to the brain
- Modulation of synaptic plasticity to address cognitive and metabolic disorders
- Utilizes a targeting approach to deliver modulators of synaptic plasticity to the brain